Phase I/II study of oxaliplatin (L-OHP) plus 5-Fluorouracil concurrent with external beam radiotherapy (EBRT) in rectosigmoid carcinoma

被引：0
|
作者：
Cajal, TRY [1 ]
Rayo, SG [1 ]
Calvo, E [1 ]
Aristu, JJ [1 ]
Villafranca, E [1 ]
Cañón, R [1 ]
Moreno, M [1 ]
Hernández, JL [1 ]
Azinovic, I [1 ]
机构：
[1] Clin Univ, Dept Oncol, Pamplona 31008, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
239
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [1] Oxaliplatin (L-OHP) does not influence the pharmacokinetics of 5-fluorouracil (5-FU)
    Joel, SP
    Richards, F
    Halstead, F
    Seymour, M
    BRITISH JOURNAL OF CANCER, 2000, 83 : 68 - 68
  • [2] Synergistic interaction between oxaliplatin (L-OHP) and 5-Fluorouracil (5-FU)
    Ward, S
    Papamichael, D
    Locke, K
    Darke, C
    Joel, S
    ANNALS OF ONCOLOGY, 1998, 9 : 39 - 39
  • [3] Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP).
    Papamichael, D
    Joel, SP
    Seymour, M
    Richards, F
    Bowerbank, M
    Slevin, ML
    BRITISH JOURNAL OF CANCER, 1998, 78 : 12 - 12
  • [4] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer
    Sato, Yasushi
    Takayama, Tetsuji
    Sagawa, Tamotsu
    Okamoto, Tetsuro
    Miyanishi, Koji
    Sato, Tsutomu
    Araki, Hironobu
    Iyama, Satoshi
    Abe, Seiichiro
    Murase, Kazuyuki
    Takimoto, Rishu
    Nagakura, Hisayasu
    Hareyama, Masato
    Kato, Junji
    Niitsu, Yoshiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 570 - 576
  • [5] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer
    Yasushi Sato
    Tetsuji Takayama
    Tamotsu Sagawa
    Tetsuro Okamoto
    Koji Miyanishi
    Tsutomu Sato
    Hironobu Araki
    Satoshi Iyama
    Seiichiro Abe
    Kazuyuki Murase
    Rishu Takimoto
    Hisayasu Nagakura
    Masato Hareyama
    Junji Kato
    Yoshiro Niitsu
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 570 - 576
  • [6] Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma
    O'Connor, Brigid M.
    Chadha, Manpreet Kaur
    Pande, Amitkumar
    Lombardo, Jeffrey C.
    Nwogu, Chumy E.
    Nava, Hector R.
    Yang, Gary
    Javle, Milind M.
    CANCER JOURNAL, 2007, 13 (02): : 119 - 124
  • [7] Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.
    Souglakos, J
    Kouroussis, C
    Ziras, N
    Malamos, N
    Potamianou, A
    Mavroudis, D
    Kakolyris, S
    Androulakis, N
    Vardakis, N
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [8] Bi-fractionated oxaliplatin (L-OHP) plus 5-fluorouracil (5FU)/leucovorin (LV) for elderly patients (pts) with advanced colorectal cancer (CRC).
    Massacesi, C
    Lippe, P
    Recchia, F
    Marcucci, F
    Rocchi, M
    Cesta, A
    Pilone, A
    Cappelletti, C
    Bonsignori, M
    Mattioli, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [9] Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Degardin, M
    Cappelaere, P
    Krakowski, I
    Fargeot, P
    Cupissol, D
    Brienza, S
    ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1996, 32B (04): : 278 - 279
  • [10] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
12345